April 11, 2017 10:00 am JST

Japan's gateway to Broadway to license own musicals to China

Shiki Theater inks first deal with Chinese company to increase earnings

Shiki Theater operates multiple theaters in Japan, including this one that opened last year in Nagoya.

TOKYO -- Shiki Theater, the company that brought "The Lion King" and many other Broadway musicals to Japan, will license its own shows to expand its earnings base.

The company has signed a licensing contract to let a Chinese theater company use its script and music for "The Cat Who Wished to Be a Man" for five years, for an undisclosed sum. The Beijing-based company will adapt Shiki's theatrical production of the American children's novel for a Chinese audience.

Shiki Theater hasn't licensed its original musicals before. Chinese performances are planned in Beijing in June and Shanghai in July. The Chinese company plans nationwide tours and targets 100 performances a year.

Shiki Theater hopes to develop the licensing business into another strong earner alongside ticket sales.

(Nikkei)

Get Insights on Asia In Your Inbox

To read the full story, Subscribe or Log in

Get your first month for $0.99

Redeemable only through the Subscribe button below

Once subscribed, you can…

  • Read all stories with unlimited access (5 articles per month without subscription)
  • Use our smartphone and tablet apps

To read the full story, Subscribe or Log in

3 months for $9
SUBSCRIBE TODAY

Take advantage of this limited offer.
Subscribe now to get unlimited access to all articles.

To read the full story, Update your account

Resubscribe now to continue reading.
BEST OFFER:
Only US$ 9.99 per month for a full-year subscription

To read the full story, Subscribe or Log in

Once subscribed, you can…

  • Read all stories with unlimited access (5 articles per month without subscription)
  • Use our smartphone and tablet apps

To read the full story, Subscribe or Log in

3 months for $9
SUBSCRIBE TODAY

Take advantage of this limited offer.
Subscribe now to get unlimited access to all articles.

To read the full story, Update your account

We could not renew your subscription.
You need to update your payment information.